Adagrasib Krazati

A drug approved for colorectal cancer. It appears in 13 clinical trials.

Oral KRAS G12C

United States FDA approved Since 2024

European Union EMA approved

Spain Not available Approved for colorectal cancer

What it is

Adagrasib is a small molecule KRAS G12C inhibitor specifically designed to target tumors harboring the KRAS G12C mutation in colorectal cancer. This targeted therapy works by covalently binding to the mutant KRAS G12C protein, effectively blocking downstream signaling pathways that drive tumor growth. Adagrasib is used in metastatic colorectal cancer patients whose tumors test positive for the KRAS G12C mutation, often in combination with cetuximab and other agents.

How it works

Adagrasib functions as a covalent inhibitor that specifically targets the KRAS G12C mutant protein by binding to the cysteine residue unique to this mutation. By locking KRAS G12C in its inactive GDP-bound state, adagrasib prevents the protein from activating critical downstream signaling pathways including RAF-MEK-ERK and PI3K-AKT that promote cancer cell proliferation and survival.

Molecular targets

KRAS G12C

Common side effects

DiarrheaNauseaFatigueVomitingAbdominal painDecreased appetiteConstipationMusculoskeletal pain

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.

Trials with this drug

5 recruiting

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer NCT07318389 Recruiting Early phase 1 United States A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 Recruiting Phase 2 United States, Australia, Belgium and 9 more A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771 Recruiting Phase 1 United States, Australia, Canada A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations NCT06412198 Recruiting Phase 1 United States KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410 Recruiting Phase 1 United States, France, Germany and 2 more A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation NCT06039384 Terminated Phase 1 United States, Italy, Spain and 1 more

See all 13 trials

Guides that may help

Written for patients and families, in plain language.

KRAS mutation: what it means for your treatmentAlmost half of colorectal cancers carry a mutation in the KRAS gene. Today the most important consequence is that anti-EGFR…Eating during chemotherapy: what the evidence supports and what it does notThere is no "anti-cancer diet" that improves the outcome of chemotherapy. What is proven is that losing weight and muscle during…Cancer-related fatigue: what actually helpsCancer-related fatigue is the most common symptom during and after treatment, and it is not fixed by sleeping more. Before…

See all guides →